Interstitial Lung Disease
Interstitial lung disease (ILD) encompasses a cluster of pulmonary disorders distinguished by the formation of scar tissue and thickening of lung tissue, leading to compromised lung function. Our company remains steadfast in its commitment to advancing knowledge and therapeutic solutions for ILD through a diverse range of services.
Overview of Interstitial Lung Disease
Interstitial lung disease refers to a range of lung disorders where the lung tissue becomes inflamed and scarred. The scarring and thickening of lung tissue occur in the interstitium, the area between the air sacs in the lungs. This leads to reduced lung capacity and compromised oxygen exchange. ILD encompasses various subtypes, including idiopathic pulmonary fibrosis (IPF), sarcoidosis, and connective tissue disease-associated ILD.
The causes of ILD can be diverse, including exposure to environmental toxins such as silica dust, asbestos fibers, and radiation therapeutics. Medications, particularly chemotherapy drugs and certain antibiotics, may also contribute to lung damage. Autoimmune diseases like rheumatoid arthritis, scleroderma, and dermatomyositis can lead to ILD as well.
Fig.1 Pathogenesis and development of ILD. (Shao T., et al., 2021)
Therapeutics Development for Interstitial Lung Disease
Several therapeutic approaches have been developed to target different aspects of the disease process.
| Name | CAS Number | Targets | Status | Phase |
|---|---|---|---|---|
| Abatacept | 332348-12-6 | T-cells | Approved | Phase 2 |
| Acetylcysteine | 616-91-1 | - | Approved | Phase 2 |
| Alemtuzumab | 216503-57-0 | CD52 | Approved | Phase 2 |
| Amitriptyline | 50-48-6 | Antidepressant | Approved | Phase 2 |
| Alkylating Agents | - | - | Unknown | Phase 3 |
Our Services
At our esteemed organization, we are dedicated to providing state-of-the-art solutions for the diagnostics and therapy development of interstitial lung disease (ILD). We invite you to click on the links below to explore the range of therapy development services we offer, tailored to meet your specific requirements.
In order to gain deeper insights into the intricate mechanisms of interstitial lung disease (ILD) and to evaluate the effectiveness of potential therapeutic interventions, the utilization of animal and in vitro models is paramount. Our company boasts a wealth of expertise in developing highly relevant animal models that faithfully replicate the pathogenesis of ILD. Moreover, our profound proficiency in developing advanced in vitro models empowers us to delve into the intricate cellular and molecular mechanisms underlying ILD, facilitating the screening of promising drug candidates.
Fibrotic Lung Disease Models
One commonly used animal model for pulmonary fibrosis is the bleomycin-induced model. Bleomycin, a chemotherapeutic agent with known fibrogenic properties, is administrated to induce lung injury and subsequent fibrotic remodeling.
RA-ILD Animal Models
To mimic the pathological features of rheumatoid arthritis-associated interstitial lung disease (RA-ILD), our experts utilize various methods, including adjuvants such as complete Freund's adjuvant (FCA), collagen type II (CII), and gene manipulation techniques.
We offer comprehensive cell-based model development services tailored to the specific research needs of our clients. These models utilize cultured cells, often derived from primary lung cells or immortalized cell lines, to recreate the cellular environment and interactions that occur within the lung tissue.
Lung organoids, generated from pluripotent stem cells or adult lung epithelial cells, closely resemble the cellular composition and architecture of the lung tissue. We offer state-of-the-art organoid model development services, harnessing the potential of this technology to advance ILD research.
Our team of scientists conducts in-depth studies to evaluate the safety, efficacy, and pharmacokinetics of potential therapeutic agents. In addition to the extensive array of services and models discussed earlier, our company excels in creating personalized solutions and designing disease models that are precisely tailored to your specific needs. We take immense pride in our capacity to adapt and customize our offerings to cater to the individual requirements of each client. If our comprehensive range of services has captured your interest, we wholeheartedly urge you to reach out to us without any hesitation.
References
- Shao T., et al. "Interstitial lung disease in connective tissue disease: a common lesion with heterogeneous mechanisms and treatment considerations." Frontiers in immunology 12 (2021): 684699.
- Karampitsakos Theodoros, et al. "Biologic treatments in interstitial lung diseases." Frontiers in medicine 6 (2019): 41.